Riskpilot← Back to searchSign inGet full accessDLX PHARMA SOLUTIONS AB
ABBankruptOrg 5591851703Other professional, scientific and technical activities n.e.c. · NACE 7490Est. 20180 employees
Revenue 2020
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2020
SEK 0
0 employees
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 0 | — |
| Total assets | SEK 50K | +0% |
| Equity | SEK 50K | +0% |
| Employees | 0 | — |
Legal name
DLX PHARMA SOLUTIONS AB
Org number
5591851703
Legal form
Aktiebolag
NACE code
7490 · Other professional, scientific and technical activities n.e.c.
Founded
12 december 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Föremålet för bolagets verksamhet är att bedriva försäljning av konsulttjänster inom hälsa och medical, evenemang och aktiviteter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | — | — |
| Depreciation & amort. | −0 | −0 |
| EBIT | 0 | 0 |
| Net financials | — | — |
| Profit before tax | 0 | 0 |
| Tax | −0 | −0 |
| Net profit | 0 | 0 |
| Item | 2019 | 2020 |
|---|---|---|
| Total assets | 50 | 50 |
| Equity | 50 | 50 |
| Long-term debt | 0 | 0 |
| Short-term debt | 0 | 0 |
| Total debt | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20192020
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20192020
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20192020
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20192020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192020
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20192020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-12-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MO Liquidator | Liquidator | 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (6) | ||
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2022 – 2023 | |
| Deputy Board Member | 2022 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DLX PHARMA SOLUTIONS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Olof Hilmersson | Liquidator | 0 companies |
| Bo Richard Joakim Brezén | Board of Directors | 0 companies |
| Jan Trotter | Deputy Board Member | 0 companies |
| Kristina Linnéa Fredriksson | Deputy Board Member | 0 companies |
| Per Jonas Fredriksson | Board of Directors | 0 companies |
| Hans Fredrik Schmalholz | Board of Directors | 0 companies |
| Erik Yngve Nordenquist | Deputy Board Member | 0 companies |